FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945129359> ?p ?o ?g. }

• W2945129359 abstract "Background Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors (SSRIs) and has been studied in many randomised controlled trials (RCTs). However, these comparative studies provided contrasting findings and systematic reviews of RCTs have always considered the SSRIs as a group, and evidence applicable to this group of drugs might not be applicable to paroxetine alone. The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics (TCAs), SSRIs and newer or non‐conventional agents. Objectives 1. To determine the efficacy of paroxetine in comparison with other anti‐depressive agents in alleviating the acute symptoms of Major Depressive Disorder. 2. To review acceptability of treatment with paroxetine in comparison with other anti‐depressive agents. 3. To investigate the adverse effects of paroxetine in comparison with other anti‐depressive agents. Search methods We searched the Cochrane Depression, Anxiety and Neurosis Review Group's Specialized Register (CCDANCTR, to 30 September 2012), which includes relevant randomised controlled trials from the following bibliographic databases: The Cochrane Library (all years), EMBASE (1974 to date), MEDLINE (1950 to date) and PsycINFO (1967 to date). Reference lists of relevant papers and previous systematic reviews were handsearched. Pharmaceutical companies marketing paroxetine and experts in this field were contacted for supplemental data. Selection criteria All randomised controlled trials allocating participants with major depression to paroxetine versus any other antidepressants (ADs), both conventional (such as TCAs, SSRIs) and newer or non‐conventional (such as hypericum). For trials which had a cross‐over design, only results from the first randomisation period were considered. Data collection and analysis Two review authors independently checked eligibility and extracted data using a standard form. Data were then entered in RevMan 5.2 with a double‐entry procedure. Information extracted included study and participant characteristics, intervention details, settings and efficacy, acceptability and tolerability measures. Main results A total of 115 randomised controlled trials (26,134 participants) were included. In 54 studies paroxetine was compared with older ADs, in 21 studies with another SSRI, and in 40 studies with a newer or non‐conventional antidepressant other than SSRIs. For the primary outcome (patients who responded to treatment), paroxetine was more effective than reboxetine at increasing patients who responded early to treatment (Odds Ratio (OR): 0.66, 95% Confidence Interval (CI) 0.50 to 0.87, number needed to treat to provide benefit (NNTb) = 16, 95% CI 10 to 50, at one to four weeks, 3 RCTs, 1375 participants, moderate quality of evidence), and less effective than mirtazapine (OR: 2.39, 95% CI 1.42 to 4.02, NNTb = 8, 95% CI 5 to 14, at one to four weeks, 3 RCTs, 726 participants, moderate quality of evidence). Paroxetine was less effective than citalopram in improving response to treatment (OR: 1.54, 95% CI 1.04 to 2.28, NNTb = 9, 95% CI 5 to 102, at six to 12 weeks, 1 RCT, 406 participants, moderate quality of evidence). We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute (six to 12 weeks), early (one to four weeks), or longer term follow‐up (four to six months). Paroxetine was associated with a lower rate of adverse events than amitriptyline, imipramine and older ADs as a class, but was less well tolerated than agomelatine and hypericum. Included studies were generally at unclear or high risk of bias due to poor reporting of allocation concealment and blinding of outcome assessment, and incomplete reporting of outcomes. Authors' conclusions Some possibly clinically meaningful differences between paroxetine and other ADs exist, but no definitive conclusions can be drawn from these findings. In terms of response, there was a moderate quality of evidence that citalopram was better than paroxetine in the acute phase (six to 12 weeks), although only one study contributed data. In terms of early response to treatment (one to four weeks) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine. However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point. Even if some differences were identified, the findings from this review are better thought as hypothesis forming rather than hypothesis testing and it would be reassuring to see the conclusions replicated in future trials. Finally, most of included studies were at unclear or high risk of bias, and were sponsored by the drug industry. The potential for overestimation of treatment effect due to sponsorship bias should be borne in mind." @default.
• W2945129359 created "2019-05-29" @default.
• W2945129359 creator A5002968416 @default.
• W2945129359 creator A5003080551 @default.
• W2945129359 creator A5007077090 @default.
• W2945129359 creator A5025108726 @default.
• W2945129359 creator A5032283932 @default.
• W2945129359 creator A5037977828 @default.
• W2945129359 creator A5039199295 @default.
• W2945129359 creator A5040247919 @default.
• W2945129359 creator A5041725712 @default.
• W2945129359 creator A5085050194 @default.
• W2945129359 date "2014-04-03" @default.
• W2945129359 modified "2023-10-02" @default.
• W2945129359 title "Paroxetine versus other anti-depressive agents for depression" @default.
• W2945129359 cites W114368807 @default.
• W2945129359 cites W1505837991 @default.
• W2945129359 cites W1516838546 @default.
• W2945129359 cites W1548699309 @default.
• W2945129359 cites W1591259115 @default.
• W2945129359 cites W1700015166 @default.
• W2945129359 cites W1714980748 @default.
• W2945129359 cites W1810544686 @default.
• W2945129359 cites W1828984482 @default.
• W2945129359 cites W1868235462 @default.
• W2945129359 cites W1904816587 @default.
• W2945129359 cites W1964162160 @default.
• W2945129359 cites W1964450221 @default.
• W2945129359 cites W1964502734 @default.
• W2945129359 cites W1965454717 @default.
• W2945129359 cites W1965492856 @default.
• W2945129359 cites W1967378279 @default.
• W2945129359 cites W1968950664 @default.
• W2945129359 cites W1969654279 @default.
• W2945129359 cites W1970503958 @default.
• W2945129359 cites W1970983150 @default.
• W2945129359 cites W1974118745 @default.
• W2945129359 cites W1974751522 @default.
• W2945129359 cites W1975570987 @default.
• W2945129359 cites W1976841336 @default.
• W2945129359 cites W1976905142 @default.
• W2945129359 cites W1977708183 @default.
• W2945129359 cites W1977843945 @default.
• W2945129359 cites W1978588976 @default.
• W2945129359 cites W1978592348 @default.
• W2945129359 cites W1978602213 @default.
• W2945129359 cites W1978686539 @default.
• W2945129359 cites W1980966169 @default.
• W2945129359 cites W1980978852 @default.
• W2945129359 cites W1982842917 @default.
• W2945129359 cites W1985936858 @default.
• W2945129359 cites W1986732478 @default.
• W2945129359 cites W1986818267 @default.
• W2945129359 cites W1988332784 @default.
• W2945129359 cites W1990055835 @default.
• W2945129359 cites W1991137562 @default.
• W2945129359 cites W1991536770 @default.
• W2945129359 cites W1991887171 @default.
• W2945129359 cites W1994862345 @default.
• W2945129359 cites W1994893078 @default.
• W2945129359 cites W1995142365 @default.
• W2945129359 cites W1996789419 @default.
• W2945129359 cites W1997415946 @default.
• W2945129359 cites W1997544731 @default.
• W2945129359 cites W1997797256 @default.
• W2945129359 cites W2000769256 @default.
• W2945129359 cites W2001307836 @default.
• W2945129359 cites W2001818277 @default.
• W2945129359 cites W2005911658 @default.
• W2945129359 cites W2006175454 @default.
• W2945129359 cites W2009284028 @default.
• W2945129359 cites W2010091722 @default.
• W2945129359 cites W2011932878 @default.
• W2945129359 cites W2012329439 @default.
• W2945129359 cites W2013156907 @default.
• W2945129359 cites W2013445513 @default.
• W2945129359 cites W2014017445 @default.
• W2945129359 cites W2015979089 @default.
• W2945129359 cites W2016325373 @default.
• W2945129359 cites W2016865081 @default.
• W2945129359 cites W2018434620 @default.
• W2945129359 cites W2018545462 @default.
• W2945129359 cites W2018650790 @default.
• W2945129359 cites W2022032351 @default.
• W2945129359 cites W2022277526 @default.
• W2945129359 cites W2022664023 @default.
• W2945129359 cites W2022866457 @default.
• W2945129359 cites W2026973648 @default.
• W2945129359 cites W2027993289 @default.
• W2945129359 cites W2028453451 @default.
• W2945129359 cites W2030116324 @default.
• W2945129359 cites W2031930150 @default.
• W2945129359 cites W2033089307 @default.
• W2945129359 cites W2033890227 @default.
• W2945129359 cites W2034106398 @default.
• W2945129359 cites W2035539241 @default.
• W2945129359 cites W2035679019 @default.
• W2945129359 cites W2035853632 @default.
• W2945129359 cites W2036861336 @default.
• W2945129359 cites W2037227674 @default.

• next